Figures & data
Figure 1. Proportion of patients initiating index TNFi treatment with etanercept, adalimumab, infliximab, golimumab, and certolizumab pegol.
Table 1. Patient baseline characteristics.
Figure 2. Treatment patterns in the (A) 12-month post-index period for all patients and (B) 12-month post-switch period for all patients who switched to a second-line non-index TNFi or non-TNFi biologic DMARD in the 12-month post-index period.
Table 2. Concomitant use of csDMARDs and time on treatment with index TNFi and post-switch biologic DMARDs.
Figure 3. Unadjusted mean (SD) RA-related costs in the 12-month period following index TNFi prescription (A) and in the 12-month period following switch from index TNFi (B).
Supplemental material
